Reuters logo
BRIEF-4SC resolves on capital increase to advance its drug development programs
June 12, 2017 / 4:13 PM / 3 months ago

BRIEF-4SC resolves on capital increase to advance its drug development programs

June 12 (Reuters) - 4SC AG

* DGAP-ADHOC: 4SC AG RESOLVES TO ISSUE NEW SHARES TO CONTINUE TO ADVANCE ITS DRUG DEVELOPMENT PROGRAMS FOR RESMINOSTAT, 4SC-202 AND 4SC-208

* IS PLANNING A CASH CAPITAL INCREASE BY WAY OF A RIGHTS OFFERING FOR EXISTING SHAREHOLDERS. A TOTAL OF UP TO APPROXIMATELY 16.4 MILLION NEW SHARES WILL BE OFFERED FOR SUBSCRIPTION

* SUBSCRIPTION RATIO WILL BE 29:25

* SUBSCRIPTION PERIOD IS SCHEDULED TO BEGIN ON 16 JUNE 2017 AND END ON 3 JULY 2017 AT NOON

* SUBSCRIPTION PRICE PER NEW SHARE IS EXPECTED TO BE DETERMINED ON 28 JUNE 2017

* AIMS TO RAISE TOTAL GROSS PROCEEDS OF BETWEEN EUR 44 AND 56 MILLION FROM CASH CAPITAL INCREASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below